Search

Your search keyword '"Raoul, J.L."' showing total 45 results
Start Over Author "Raoul, J.L."
45 results on '"Raoul, J.L."'

1. Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)

Author

Veziant, Julie, Bouché, Olivier, Aparicio, T., Barret, M., El hajbi, F., Lepilliez, V., Lesueur, P., Maingon, P., Pannier, D., Quero, L., Raoul, J.L., Renaud, F., Seitz, J.F., Serre, A.A., Vaillant, E., Vermersch, M., Voron, T., Tougeron, D., and Piessen, Guillaume

Published
2023
Full Text
View/download PDF

3. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

7. Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of doxorubicin

Author

Raoul, J.L., Heresbach, D., Bretagne, J.F., Ferrer, D. Bentue, Duvauferrier, R., Bourget, P., Messner, M., and Gosselin, M.

Subjects
Doxorubicin -- Physiological aspects, Liver cancer, Radioisotopes -- Health aspects, Health
Abstract

Background. This study evaluated the effects of an association of ethiodized oil (Lipiodol Ultra Fluide, Laboratories Guerbet, Aulnay-sous-Bois, France), with or without gelatin sponge, with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) on the biodistribution and kinetics of doxorubicin during intraarterial injection. Methods. Eighteen patients with hepatocellular carcinoma on cirrhotic liver received a therapeutic injection into the hepatic artery of 50 mg of doxorubicin alone (Group 1; n = 4), or emulsified in 10 ml of ethiodized oil and 2.5 ml of ioxaglate (Hexabrix, Laboratories Guerbet) with (Group 2; n = 7) or without (Group 3; n = 7) gelatin sponge embolization. Before treatment, the absence of intrahepatic shunts was verified by an injection of technetium-labeled albumin macroaggregates. The biodistribution of doxorubicin was studied on two fronts: (1) pharmacokinetic - by measurement of the doxorubicin blood level during the 48 hours after injection; and (2) scintigraphic (2 mg of doxorubicin were labeled with 2 mCi of iodine 131) - by examination of the scintigrams and calculation of the following parameters: tumorous liver/nontumorous liver binding ratio (T/NT ratio), liver/liver + lungs + abdomen binding ratio, and doxorubicin half-life in tumorous tissue. Results. Pharmacokinetics results showed the following: the peak plasma concentration was significantly higher in Group 1 as compared with Groups 2 or 3 (Group 1: 2.1 [+ or -] 0.9 mg/ml; Group 2: 0.9 [+ or -] 0.3 mg/ml; Group 3: 05 [+ or -] 0.2 mg/ml); the area under curve calculated from time zero to 1 hour was lower in Groups 2 and 3 compared with Group 1. Examination of the scintigrams showed the following: diffuse activity throughout the organism (Group 1), diffuse activity with strong hepatic and tumorous binding (Group 2), and mostly hepatic and tumoral binding (Group 3). The liver/liver + lungs + abdomen binding ratio was 28% [+ or -] in Group 1, 36% [+ or -] 5% in Group 2, and 63% [+ or -] 7% in Group 3. The T/NT ratios were 1.0 [+ or -] 0 (Group 1), 1.5 [+ or -] 0.1 (Group 2), and 4.7 [+ or -] 0.5 (Group 3). The doxorubicin half-lives in tumorous tissue were 0.7 [+ or -] 0.1 days (Group 1), 1.8 [+ or -] 0.2 days (Group 2), and 2.6 days (n = 1; Group 3). Conclusions. This study shows (1) that the association of ethiodized oil with doxorubicin lowers the peak concentration of doxorubicin and increases the intratumoral concentration and half-life of doxorubicin, and (2) that these kinetic ameliorations are even more pronounced after embolization. Therefore, from a kinetic standpoint, the doxorubicin-ethiodized oil-gelatin sponge association is the best. Cancer 1992; 70:585-590.

Published
1992

8. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

Author

Bachet, J.B., primary, Lucidarme, O., additional, Levache, C.B., additional, Barbier, E., additional, Raoul, J.L., additional, Lecomte, T., additional, Desauw, C., additional, Brocard, F., additional, Pernot, S., additional, Breysacher, G., additional, Lagasse, J.P., additional, Di Fiore, F., additional, Etienne, P.L., additional, Dupuis, O.J.M., additional, Aleba, A., additional, Lepage, C., additional, Taieb, J., additional, Dahan, L., additional, Auby, D., additional, Khemissa, F., additional, Ghiringhelli, F., additional, Nguyen, S., additional, Bedjaoui, A., additional, Terrebonne, E., additional, Thaury, J., additional, and Baconnier, M., additional

Published
2018
Full Text
View/download PDF

9. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Aparicio, Thomas, primary, Ducreux, Michel, additional, Faroux, Roger, additional, Barbier, Emilie, additional, Manfredi, Sylvain, additional, Lecomte, Thierry, additional, Etienne, Pierre-Luc, additional, Bedenne, Laurent, additional, Bennouna, Jaafar, additional, Phelip, Jean-Marc, additional, François, Eric, additional, Michel, Pierre, additional, Legoux, Jean-Louis, additional, Gasmi, Mohamed, additional, Breysacher, Gilles, additional, Rougier, Philippe, additional, De Gramont, Aimery, additional, Lepage, Come, additional, Bouché, Olivier, additional, Seitz, Jean-François, additional, Adenis, A., additional, Alessio, A., additional, Aouakli, A., additional, Azzedine, A., additional, Bedjaoui, A., additional, Bidault, A., additional, Blanchi, A., additional, Botton, A., additional, Cadier-Lagnes, A., additional, Fatisse, A., additional, Gagnaire, A., additional, Gilbert, A., additional, Gueye, A., additional, Hollebecque, A., additional, Lemaire, A., additional, Mahamat, A., additional, Marre, A., additional, Patenotte, A., additional, Rotenberg, A., additional, Roussel, A., additional, Thirot-Bidault, A., additional, Votte, A., additional, Weber, A., additional, Zaanan, A., additional, Dupont-Gossart, A.C., additional, Villing, A.L., additional, Queuniet, A.M., additional, Coudert, B., additional, Denis, B., additional, Garcia, B., additional, Lafforgue, B., additional, Landi, B., additional, Leduc, B., additional, Linot, B., additional, Paillot, B., additional, Rhein, B., additional, Winkfield, B., additional, Barberis, C., additional, Becht, C., additional, Belletier, C., additional, Berger, C., additional, Bineau, C., additional, Borel, C., additional, Brezault, C., additional, Buffet, C., additional, Cornila, C., additional, Couffon, C., additional, De La Fouchardière, C., additional, Giraud, C., additional, Lecaille, C., additional, Lepere, C., additional, Lobry, C., additional, Locher, C., additional, Lombard-Bohas, C., additional, Paoletti, C., additional, Platini, C., additional, Rebischung, C., additional, Sarda, C., additional, Vilain, C., additional, Briac-Levaché, C., additional, Auby, D., additional, Baudet-Klepping, D., additional, Bechade, D., additional, Besson, D., additional, Cleau, D., additional, Festin, D., additional, Gargot, D., additional, Genet, D., additional, Goldfain, D., additional, Luet, D., additional, Malka, D., additional, Peré-Vergé, D., additional, Pillon, D., additional, Sevin-Robiche, D., additional, Smith, D., additional, Soubrane, D., additional, Tougeron, D., additional, Zylberait, D., additional, Carola, E., additional, Cuillerier, E., additional, Dorval Danquechin, E., additional, Echinard, E., additional, Janssen, E., additional, Maillard, E., additional, Mitry, E., additional, Norguet-Monnereau, E., additional, Suc, E., additional, Terrebonne, E., additional, Zrihen, E., additional, Pariente, E.A., additional, Almaric, F., additional, Audemar, F., additional, Bonnetain, F., additional, Desseigne, F., additional, Dewaele, F., additional, Di Fiore, F., additional, Ghiringhelli, F., additional, Husseini, F., additional, Khemissa, F., additional, Kikolski, F., additional, Morvan, F., additional, Petit-Laurent, F., additional, Riot, F., additional, Subtil, F., additional, Zerouala-Boussaha, F., additional, Caroli-Bosc, F.X., additional, Boilleau-Jolimoy, G., additional, Bordes, G., additional, Cavaglione, G., additional, Coulanjon, G., additional, Deplanque, G., additional, Gatineau-Saillant, G., additional, Goujon, G., additional, Medinger, G., additional, Roquin, G., additional, Brixi-Benmansour, H., additional, Castanie, H., additional, Lacroix, H., additional, Maechel, H., additional, Perrier, H., additional, Salloum, H., additional, Senellart, H., additional, Baumgaertner, I., additional, Cumin, I., additional, Graber, I., additional, Trouilloud, I., additional, Boutin, J., additional, Butel, J., additional, Charneau, J., additional, Cretin, J., additional, Dauba, J., additional, Deguiral, J., additional, Egreteau, J., additional, Ezenfis, J., additional, Forestier, J., additional, Goineau, J., additional, Lacourt, J., additional, Lafon, J., additional, Martin, J., additional, Meunier, J., additional, Moreau, J., additional, Provencal, J., additional, Taieb, J., additional, Thaury, J., additional, Tuaillon, J., additional, Vergniol, J., additional, Villand, J., additional, Vincent, J., additional, Volet, J., additional, Bachet, J.B., additional, Barbare, J.C., additional, Souquet, J.C., additional, Grangé, J.D., additional, Dor, J.F., additional, Paitel, J.F., additional, Jouve, J.L., additional, Raoul, J.L., additional, Cheula, J.M., additional, Gornet, J.M., additional, Sabate, J.M., additional, Vantelon, J.M., additional, Vaillant, J.N., additional, Aucouturier, J.P., additional, Barbieux, J.P., additional, Herr, J.P., additional, Lafargue, J.P., additional, Lagasse, J.P., additional, Latrive, J.P., additional, Plachot, J.P., additional, Ramain, J.P., additional, Robin, J.P., additional, Spano, J.P., additional, Douillard, J.Y., additional, Beerblock, K., additional, Bouhier-Leporrier, K., additional, Slimane Fawzi, K., additional, Cany, L., additional, Chone, L., additional, Dahan, L., additional, Gasnault, L., additional, Rob, L., additional, Stefani, L., additional, Wander, L., additional, Baconnier, M., additional, Ben Abdelghani, M., additional, Benchalal, M., additional, Blasquez, M., additional, Carreiro, M., additional, Charbit, M., additional, Combe, M., additional, Duluc, M., additional, Fayolle, M., additional, Gignoux, M., additional, Giovannini, M., additional, Glikmanas, M., additional, Mabro, M., additional, Mignot, M., additional, Mornet, M., additional, Mousseau, M., additional, Mozer, M., additional, Pauwels, M., additional, Pelletier, M., additional, Porneuf, M., additional, Ramdani, M., additional, Schnee, M., additional, Tissot, M., additional, Zawadi, M., additional, Clavero-Fabri, M.C., additional, Gouttebel, M.C., additional, Kaminsky, M.C., additional, Galais, M.P., additional, Abdelli, N., additional, Barrière, N., additional, Bouaria, N., additional, Bouarioua, N., additional, Delas, N., additional, Gérardin, N., additional, Hess-Laurens, N., additional, Stremsdoerfer, N., additional, Berthelet, O., additional, Boulat, O., additional, Capitain, O., additional, Favre, O., additional, Amoyal, P., additional, Bergerault, P., additional, Burtin, P., additional, Cassan, P., additional, Chatrenet, P., additional, Chiappa, P., additional, Claudé, P., additional, Couzigou, P., additional, Feydy, P., additional, Follana, P., additional, Geoffroy, P., additional, Godeau, P., additional, Hammel, P., additional, Laplaige, P., additional, Lehair, P., additional, Martin, P., additional, Novello, P., additional, Pantioni, P., additional, Pienkowski, P., additional, Pouderoux, P., additional, Prost, P., additional, Ruszniewski, P., additional, Souillac, P., additional, Texereau, P., additional, Thévenet, P., additional, Haineaux, P.A., additional, Benoit, R., additional, Coriat, R., additional, Lamy, R., additional, Mackiewicz, R., additional, Beorchia, S., additional, Chaussade, S., additional, Hiret, S., additional, Jacquot, S., additional, Lavau Denes, S., additional, Montembault, S., additional, Nahon, S., additional, Nasca, S., additional, Nguyen, S., additional, Oddou-Lagraniere, S., additional, Pesque-Penaud, S., additional, Fratte, S.P., additional, Chatellier, T., additional, Mansourbakht, T., additional, Morin, T., additional, Walter, T., additional, Boige, V., additional, Bourgeois, V., additional, Derias, V., additional, Guérin-Meyer, V., additional, Hautefeuille, V., additional, Jestin Le Tallec, V., additional, Lorgis, V., additional, Quentin, V., additional, Sebbagh, V., additional, Veuillez, V., additional, Adhoute, X., additional, Coulaud, X., additional, Becouarn, Y., additional, Coscas, Y., additional, Courouble, Y., additional, Le Bricquir, Y., additional, Molin, Y., additional, Rinaldi, Y., additional, Lam, Y.H., additional, and Ladhib, Z., additional

Published
2018
Full Text
View/download PDF

10. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial

Author

Bachet, J.-B., primary, Lucidarme, O., additional, Levache, C.B., additional, Maillard, E., additional, Raoul, J.L., additional, Lecomte, T., additional, Desauw, C., additional, Brocard, F., additional, Pernot, S., additional, Breysacher, G., additional, Lagasse, J.-P., additional, Di Fiore, F., additional, Etienne, P.L., additional, Dupuis, O., additional, Aleba, A., additional, Lepage, C., additional, and Taieb, J., additional

Published
2017
Full Text
View/download PDF

11. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment

Author

Thierry, A.R., primary, El Messaoudi, S., additional, Mollevi, C., additional, Raoul, J.L., additional, Guimbaud, R., additional, Pezet, D., additional, Artru, P., additional, Assenat, E., additional, Borg, C., additional, Mathonnet, M., additional, De La Fouchardière, C., additional, Bouché, O., additional, Gavoille, C., additional, Fiess, C., additional, Auzemery, B., additional, Meddeb, R., additional, Lopez-Crapez, E., additional, Sanchez, C., additional, Pastor, B., additional, and Ychou, M., additional

Published
2017
Full Text
View/download PDF

12. SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma

Author

Vilgrain, V., primary, Bouattour, M., additional, Sibert, A., additional, Lebtahi, R., additional, Ronot, M., additional, Pageaux, G.-P., additional, Guiu, B., additional, Barraud, H., additional, Silvain, C., additional, Gérolami, R., additional, Oberti, F., additional, Raoul, J.L., additional, Costentin, C., additional, Samuel, D., additional, Dinut, A., additional, Pereira, H., additional, Chatellier, G., additional, and Castera, L., additional

Published
2017
Full Text
View/download PDF

16. A Triple Combination Tailored Therapy (Folfiri-Cetuximab) for Safe Dose Intensification: A Multicenter Phase II Proof-Of-Concept Study.

Author

Capitain, O., primary, Metges, J.P., additional, Boisdron-Celle, M., additional, Adenis, A., additional, Raoul, J.L., additional, Lecomte, T., additional, Lam, Y., additional, Faroux, R., additional, Masliah, C., additional, Poirier, A.L., additional, Berger, V., additional, Morel, A., additional, and Gamelin, E., additional

Published
2014
Full Text
View/download PDF

19. OP-02 Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: A new personalized promising concept

Author

Garin, E., primary, Lenoir, L., additional, Edeline, J., additional, Laffont, S., additional, Mesbah, H., additional, Porée, P., additional, Raoul, J.L., additional, Boudgema, K., additional, Sulpice, L., additional, Clement, B., additional, Rolland, Y., additional, and Boucher, E., additional

Published
2013
Full Text
View/download PDF

20. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601

Author

Ferrand, F., primary, Malka, D., additional, Bourredjem, A., additional, Allonier, C., additional, Bouché, O., additional, Louafi, S., additional, Boige, V., additional, Mousseau, M., additional, Raoul, J.L., additional, Bedenne, L., additional, Leduc, B., additional, Deguiral, P., additional, Faron, M., additional, Pignon, J.P., additional, and Ducreux, M., additional

Published
2013
Full Text
View/download PDF

29. P.117 Analyse longitudinale de la qualité de la vie (QdV) dans un essai randomisé de phase III : octréotide contre placebo dans le cadre du carcinome hépato-cellulaire (CHC) en phase palliative

Author

Dumas, F., primary, Barbare, J.C., additional, Aparicio, T., additional, Bouché, O., additional, Lombard-Bohas, C., additional, Faroux, R., additional, Seitz, J.F., additional, Raoul, J.L., additional, Bedenne, L., additional, and Bonnetain, F., additional

Published
2009
Full Text
View/download PDF

30. CO.133 Association Cetuximab-FOLFIRI en traitement de 1re intention du cancer colorectal métastatique : données de survie et impact du statut KRas de l’étude CRYSTAL

Author

Rougier, P., primary, Raoul, J.L., additional, Faroux, R., additional, Miglianico, L., additional, Viret, F., additional, Levaché, C.B., additional, Smith, D., additional, Rebischung, C., additional, Borel, C., additional, Seitz, J.F., additional, Husseini, F., additional, Ramée, J.F., additional, Egreteau, J., additional, and Van Cutsem, E., additional

Published
2009
Full Text
View/download PDF

31. CO.86 Essai de phase III randomisé comparant deux stratégies de chimiothérapie dans les adénocarcinomes pancréatiques métastatiques : LV5FU2-cisplatine suivi de gemcitabine en cas de progression contre la séquence inverse

Author

Dahan, L., primary, Ychou, M., additional, Gasmi, M., additional, Mitry, E., additional, Bonnetain, F., additional, Raoul, J.L., additional, Mariette, C., additional, Phelip, J.M., additional, Hammel, P., additional, Michel, P., additional, Chauffert, B., additional, Bedenne, L., additional, and Seitz, J.F., additional

Published
2009
Full Text
View/download PDF

32. CO.105 Recherche des faux-positifs puis évaluation du dosage de chromogranine A comme marqueur de suivi des carcinomes endocrines bien différenciés gastro-entéropancréatiques métastatiques (CEBDM GEP)

Author

Vezzosi, D., primary, Lombard-Bohas, C., additional, Dromain, C., additional, Ducreux, M., additional, Leboulleux, S., additional, Ruszniewski, P., additional, Guigay, J., additional, Laplanche, A., additional, Debaere, T., additional, Elias, D., additional, Schlumberger, M., additional, Mitry, E., additional, Raoul, J.L., additional, Cadiot, G., additional, and Baudin, E., additional

Published
2009
Full Text
View/download PDF

38. 289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)

Author

Raoul, J.L., primary, van Laethem, J.L., additional, Mitry, E., additional, Brezault, C., additional, Husseini, F., additional, Cals, L., additional, Peeters, M., additional, Vedovato, J.C., additional, Mueser, M., additional, and Rougier, P., additional

Published
2003
Full Text
View/download PDF

41. ‘Tomudex’ (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients: an active combination

Author

Bennouna, J., primary, Seitz, J.F., additional, Paillot, B., additional, Gamelin, E., additional, François, E., additional, Conroy, T., additional, Raoul, J.L., additional, Becouarn, Y., additional, Cvitkovic, F.Bertheault, additional, Nasca, S., additional, Ychou, M., additional, Jacob, J., additional, Smith, M., additional, Douillard, J.Y., additional, and Fandi, A., additional

Published
1999
Full Text
View/download PDF

45. Sorafenib in advanced hepatocellular carcinoma

Author

Josep M, Llovet, Sergio, Ricci, Vincenzo, Mazzaferro, Philip, Hilgard, Edward, Gane, Jean-Frédéric, Blanc, Andre Cosme, de Oliveira, Armando, Santoro, Jean-Luc, Raoul, Alejandro, Forner, Myron, Schwartz, Camillo, Porta, Stefan, Zeuzem, Luigi, Bolondi, Tim F, Greten, Peter R, Galle, Jean-François, Seitz, Ivan, Borbath, Dieter, Häussinger, Tom, Giannaris, Minghua, Shan, Marius, Moscovici, Dimitris, Voliotis, Jordi, Bruix, M, Schwartz, GBR, ESP, BEL, DEU, POL, USA, FRA, CHE, ARG, AUS, BRA, BGR, CAN, RUS, MEX, NZL, 128. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., and for the SHARP Investigators Study Group.

Subjects
Sorafenib, Male, Niacinamide, medicine.medical_specialty, Carcinoma, Hepatocellular, Pyridines, Placebo, Gastroenterology, Double-Blind Method, Internal medicine, medicine, Carcinoma, Humans, HEPATOCELLULAR CARCINOMA, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Proportional Hazards Models, business.industry, Phenylurea Compounds, Hazard ratio, Benzenesulfonates, Liver Neoplasms, General Medicine, TREATMENT, Middle Aged, medicine.disease, Interim analysis, Survival Analysis, Recurrent Hepatocellular Carcinoma, digestive system diseases, Surgery, SORAFENIB, Chemotherapy, Adjuvant, Hepatocellular carcinoma, Disease Progression, Female, raf Kinases, business, Liver cancer, medicine.drug
Abstract

none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results